Hairy cell leukemia (HCL) is a lymphoproliferative disorder of B lymphocytes. Interferons (IFNs), especially of the alpha (a) subtype, have shown a significant antitumor effect in HCL patients. However, the therapeutic effect of IFN-a is still rather limited. The purine analogue 2-chlorodeoxyadenosine (2-CdA) was reported recently to be an effective agent in the treatment of HCL. In the present study, we find that the HCL cell lines HS-1 and HS-2 as well as Eskol and its IFN-resistant clone (IRES-4) are sensitive to the cytotoxic activity of 2-CdA. Combination treatment of IFNConl and 2-CdA results in a synergistic effect at low doses but an additive inhibitory effect at higher concentrations. IRES-4 cells responded only to 2-CdA treatment. All the HCL cell lines are resistant to natural killer (NK) cell-mediated cytotoxicity (CMC) but are relatively sensitive to IFNConl -primed or interleukin-2 (IL-2)-primed NK-CMC activities. No inhibition in killing ability was measured when AIRY CELL LEUKEMIA (HCL) is a lymphoprolif-H erative disorder of B lymphocytes with pathologic manifestations usually including splenomegaly and pancytopenia.',* Interferons (IFNs), specifically of the alpha (a) subtype, have shown a significant antitumor effect in HCL patients, with improvement of hematologic parameters within the first few months of treatment.3 This response is specific because IFN-y is ineffective in this capacity: However, the therapeutic effects of IFN-a is still rather limited. One possible approach to improving the efficacy of IFN treatment is to combine it with other chemotherapeutic agents, such as purine or pyrimidine analogues.
H erative disorder of B lymphocytes with pathologic manifestations usually including splenomegaly and pancytopenia.',* Interferons (IFNs), specifically of the alpha (a) subtype, have shown a significant antitumor effect in HCL patients, with improvement of hematologic parameters within the first few months of treatment.3 This response is specific because IFN-y is ineffective in this capacity: However, the therapeutic effects of IFN-a is still rather limited. One possible approach to improving the efficacy of IFN treatment is to combine it with other chemotherapeutic agents, such as purine or pyrimidine analogues.
The adenosine deaminase-resistant purine analogue 2-chlorodeoxyadenosine (2-CdA) has been reported to be an effective agent in the treatment of HCL, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.'-' 2-CdA selectively accumulates as the 5'-triphosphate derivate in cells rich in deoxycytidine kinase resulting in DNA breaks and depletion of nicotinamide adenine dinucleotide (NAD). The cytotoxic activity of 2-CdA is independent of cell division and is myeloid s~ppressive.6.~ Presumably because of its relatively high cellular specificity, 2-CdA has been found to be remarkably devoid of the toxic side effects usually associated with other chemotherapeutic agents against cancer. rate of cellular growth14 and an increase in the expression of CD21, CD25, FMC7, and PCAl antigen^.'^ Scanning electron microscopy showed that Eskol cells incubated with IFNa underwent membranous changes with a loss of ~illosity.'~ We have investigated the direct effects of IFN-Con1 and IFNa on Eskol cells, and the indirect effect of IFN-a-induced natural killer (NK) cell activity against these cells. We found that both IFN-a and IFN-Con1 had a direct, low but significant antiproliferative effect on Eskol cells14 and plays a key role in the regulation of NK activity against these HCL-like cells. 16 Recently, IFN-a-resistant Eskol cell clones (IRES) were established in our laboratory. In the present study, we used both Eskol and IRES-4 clone as well as the HCL cell lines HS-1 and HS-2.
NK cells function as an early defense mechanism against tumor cells and their metastases. A model that divides the interaction between NK cells and NK target cells into several phases has been proposed."*'' The NK cell first has to bind to the target cell through a receptor that recognizes a specific structure on the target cell surface. The second phase involves the activation of intracellular processes in the NK cells, which are probably triggered by the target cell, and leads to a rearrangement of the NK cytoplasmic granules toward the site of binding with the target cell. The next phase is the release of some of the granules or their contents from the effector cell. The cytotoxic molecule (NK cytotoxic factor, NKCF) would then bind to the target cell, presumably at sites separated from those recognized by the NK IFN plays a central role in the regulation of NK cell activity. On the one hand, IFN increases the lytic activity of NK effector cells against sensitive target cells and induces NK-mediated cytotoxic activity against normally resistant target cells. On the other hand, pretreatment of target cells with IFN decreases their sensitivity to NK cell-mediated cytotoxicity (NK-CMC).l9 Eskol cells were found to be completely resistant to NK-CMC but were relatively sensitive to IFN-a-primed NK cell activity and to lymphokine-activated killer (LAK) cell activity. We reported that the resistance of Eskol cells to NK-CMC is because ofthe low binding of Eskol to effector cells. 16 In this article, we report that a combination of IFN-Con1 and 2-CdA resulted in an additive cell growth inhibitory effect on the HCL cell lines. Moreover, at relatively very low doses, those at which the effect of each drug alone is unmeasurable, the combination treatment resulted in a synergistic effect. The IFN-resistant HCL clone (IRES-4) responded only to 2-CdA. All the HCL cell types are NK-CMC-resistant cells but are sensitive to IFN-Con 1 -primed or interleukin-2 (IL-2)-primed NK cell activities. No inhibition in the NK killing activity was found when only the NK effector cells were treated with 2-CdA. Moreover, there is no stimulatory or inhibitory effects of 2-CdA on IFN-Con 1 or 11-2 activation of NK cells. On the other hand, 2-CdA used alone increases the susceptibility of the HCL cell lines to NK-CMC, whereas IFN-Con1 alone protects HS-I, HS-2, and Eskol cells but not the IFN-resistant clone IRES-4 from NK-CMC. The combination of IFN-Con 1 and 2-CdA abolishes the protective effect against NK-CMC induced by IFN-a in the IFN-sensitive HCL cells. Thus, combination of TFN-Con1 and 2-CdA results in at least an additive in vitro enhancement of the direct cell growth inhibitory activity of each treatment alone and in an increased efficacy of the NK-CMC activity against the IFN-sensitive HCL cell lines.
MATERIALS AND METHODS
The HCL-like cell line, Eskol,15 IFN-resistant Eskol clone (IRES-4), the HCL cell lines HS-I and HS-2 obtained from splenocytes of patients with HCL (kindly provided by Dr H. Ozer, North Carolina University) and the chronic myelogenous leukemia cell line K-562 (ATCC CCL 243) were used as target cells. The Eskol cell line has previously been described. 15 The IFN-resistant Eskol clones were isolated by incubating Eskol cells in the presence of IFNCon1 ( I X lo6 U/mL) for 4 months. Every 3 days, cells were centrifugated, washed, and resuspended in media and fresh IFN-Con1 .
After 4 months, cells were cloned in soft agar containing IFN-Con I ( I X IO6 U/mL) for 20 days and four individuals' clones were isolated and termed IRES-1, IRES-2, IRES-3, and IRES-4. The IRES clones were found to be completely resistant, on the basis of cell counts, to the antiproliferative effect of IFN-a or IFN-Con I at 300 to 30,000 U/mL (0. N. Ozes, Z. Reiter, S. Klein, and M. W. Taylor, manuscript in preparation). The clone IRES-4 was used in all further experiments. Normal fibroblasts (FS-4 cells) were used as control. The HCL cell lines as well as K-562 cells were grown and assayed in RPMI 1640 medium (GIBCO Inc, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS), L-glutamine (2 mmol/L), penicillin (100 U/mL), and streptomycin (100 pg/mL) at 37°C in a Target cells.
humidified 5% COz incubator. FS-4 cells were grown in minimal essential media supplemented as described.
Purification of effector cells was done as described.'O Briefly, nonadherent human leukocytes were purified from freshly collected peripheral blood of healthy donors. The cells were fractionated by sedimentation on Ficoll-Paque (Pharmacia LKB Biotechnology Inc, Piscataway, NJ) followed by adsorption on nylonwool columns. The nonadherent cells were used as the effector cell population in the experimental procedures.
Recombinant consensus IFN-Con1 (specific activity 3 X IO9 U/mg) and human recombinant IL-2 ("Ala-125," specific activity >5 X IO6 U/mg) were provided by L. Blatt The HCL cells ( 1 X 10' cells/ mL) were treated as described. Cell samples were harvested at 24-hour intervals and counted following trypan blue staining for cell viability. FS-4 cells ( 5 X IO4 cells/well) were treated as described. Following incubation, the cells were stained with crystal-violet (8% in methanol) and the dye extracted with sodium citrate (0.1 mol/L) in 50% ethanol (50 pL/well). Absorbance was read at 590 nm. Growth inhibition is expressed as the percentage increase in cell number in the treated cultures relative to the increase in cell number in untreated cultures according to the formula: % relative growth = [(I,, -Co)/ (C, -C,)] X 100, where I, is the number of treated cells at day n; C, is the number of control cells at day n; and C, is the number of control cells at day 0. Each datum point represents an average of triplicate assays.
HCL and K-562 cells were labeled with "Cr-sodium chromate (specific activity 393.2 mCi/mg; New England Nuclear, Boston, MA) for 1.5 hours. The cells were washed twice with phosphate-buffered saline (PBS), suspended in RPMI 1640 media to a density of 1 X IO5 cells/mL, and dispensed into 96-well conical-bottom microtiter plates ( IO4 cells/ well; 100 pL). FS-4 cells were seeded in flat-bottom 96-well plates for 12 hours ( IO4 cells/well). The cells were labeled with "Cr-sodium chromate for 8 hours. Following labeling, the cells were washing three times with PBS. Various amounts of NK effector cells were then added (final volume 200 pL/well) for 4 hours at 37°C. Aliquots of the supernatants were collected and their radioactivity measured in a y-counter (Beckman Instruments, Irvine, CA). Total cycles per minute (cpm) was obtained by adding Triton X-100 (2%, 100 pL/ well, Sigma Chemical Co, St Louis, MO) to wells with target cells alone. Spontaneous release was determined in wells containing target cells alone. Data are expressed as the percentage of specific release according to the formula: specific release (%) = [(cpm, -cpm,)/ (cpm, -cpm.)] X 100, where cpm, were experimental released cpm; cpm, were spontaneously released cpm; and cpm, were total cpm. Each datum point represents an average of triplicate assays.
Target cells (Eskol and K-562) were examined for their capacity to form conjugates with effector cells. NK effector cells ( I X IO6 cells/ml; 100 pL) and target cells ( I X IO4 cells/mL; 100 pL) were mixed, centrifuged (12Og; 5 min) and incubated at 37°C for 30 minutes. After gentle resuspension, the cells were stained with trypan blue. At least 500 target cells were counted and the number of target cells bound to two or more lymphocytes was divided by the total number of target cells, giving the percentage of conjugate formation. In addition, the number of trypan blue- Various amounts of unlabeled K-562 or Eskol cells were used as competitive targets for NK activity. Competitor cells were mixed with effector cells ( lo6 cells/well) and incubated for 15 minutes at 37°C. 5'Cr-labeled Eskol cells (2 X 10" cells/well) were then added (final volume 150 pL/well), the plates were incubated, and specific released radioactivity was assayed as previously described.
Cell-free supernatants containing NKCF were generated by incubation of mixed effector and target cells, either K-562 or Eskol (effector:target ratio 501) in serum-free medium. Cultures of either effector or target cells alone were used as controls. After 48 hours of incubation (37°C in 5% COz), the supematants were collected, filtered through a 22-pm Millipore filter (Millipore Co, Bedford, MA), and stored at -70°C until further use. Eskol cells were used as NKCF inducers in order to determine the effect of IFN-Conl, 2-CdA, or combination on this level of the killing process. K-562 cells were used as NKCF inducers to supply high cytotoxic supernatants (containing NKCF) in order to study the effect of IFN-Conl, 2-CdA, or combination on Eskol cell susceptibility to NKCF. Preliminary resultsi6 revealed that the ability of Eskol cells as NKCF inducers is lower than that of K-562 cells. Supematants from cultures of effector cells alone showed a low level of cytotoxicity 1.4% ? 0.4% when Eskol cells were used as targets and 2.9% f 0.8% when K-562 cells were used as targets. Supematants from cultures of either Eskol or K-562 cells alone had no (<I%) cytotoxic effect over the spontaneous release of Wr.
"Cr-labeled target cells, either Eskol or K-562 (104 cells/well, in 50 pL serum-free media) were sedimented in 96-well plates. Supernatants containing various amounts (10, 50, or 100 pL/well) of crude NKCF preparations were added and the total volume was 150 pL/well. The cultures were incubated for 20 to 24 hours. Aliquots of the supernatants were then collected and specific released radioactivity was assayed as previously described.
Statistical analysis. All the results are expressed as an arithmetic mean f standard error of the mean (SEM). Comparisons were carried out by a Student's t-test.
Cold target competition assay.
Production of crude NKCF preparations.
Assay for NKCF activity.
RESULTS
The effect of 2-CdA on growth of HCL cells. Eskol (Fig   IA) , IRES-4 (Fig IB) , HS-1 (Fig IC) , and HS-2 ( Fig ID) cells were incubated in increasing concentrations of 2-CdA for various time periods. The various HCL cells exhibited a similar pattern of growth inhibition by 2-CdA, although Eskol and IRES-4 cells (Fig I A , B) were relatively more sensitive than HS-1 and HS-2 HCL lines (Fig lC, D) . After 24 hours of incubation with 2-CdA, only cells exposed to 1 pg/mL of 2-CdA were significantly ( P < .05) inhibited. A significant ( P < .05 to P < .005) inhibitory effect of 2-CdA was found after 72 hours of incubation at all concentrations of 2-CdA above I ng/mL when compared with untreated cultures. FS-4 cells (Fig IE) responded only to relatively high doses of 2-CdA (100 ng/mL and 1 pg/mL). A significant ( P < .05) growth inhibition of FS-4 cells was seen only after 72 hours of incubation ( Fig 1E) at these high concentrations.
A synergistic/additive effect of IFN-Con1 and 2-CdA on HCL cell growth inhibition. HCL cell lines were treated in combination with IFN-Con1 and 2-CdA for various periods of incubation time. After 24 hours of incubation, a significant (P < .05 to P < .01) synergistic effect was found on cell growth when Eskol (Fig 2A) , HS-1 (Fig 2C) , and HS-2 ( Fig 2D) cells were treated with 300 U/mL of IFN-Con1 and either 1, IO, or 100 ng/mL of 2-CdA. Neither IFN-Con1 alone nor 2-CdA (in that concentrations) alone exhibits cell growth inhibitory activity after 24 hours. Combination of I N -C o n 1 and relatively high levels of 2-CdA (1 pg/mL) resulted in a n additive cell growth inhibitory effect following 24 hours of incubation.
A significant ( P < .05 to P < .01) additive effect, compared with untreated cells, was also found in Eskol, HS-I, and HS-2 cultures treated with IFN-Con 1 and all the tested concentrations of 2-CdA after 3 days of incubation. The cell growth inhibitory effects were found to be both time and dose dependent (Fig 2A, C, D) . IRES-4 cells responded only to 2-CdA treatment but not to IFN-a (Fig 2B) . Neither additive nor synergistic effects were found following combination treatment of IFN-Con1 and 2-CdA in IRES-4 cells. In FS-4 cells, only an additive cell growth inhibitory effect was seen (Fig 2E) when the cells were treated with high doses of 2-CdA and IFN-Con1 for 3 days.
2-CdA affects neither NK cell activity nor NK cell activation by IFN or IL-2. 2-CdA treatment has no effect on the killing activity of NK effector cells when targets were either the NKresistant Eskol cells or the NK-sensitive K-562 cells (not shown). Combination treatment (8 h) of IFN-Con1 (300 U/ mL) and 2-CdA resulted in similar levels of N K activation as IFN treatment alone. Similarly, 2-CdA did not affect activation of NK cells by IL-2 (100 U/mL). Various doses of 2-CdA (1 ng/mL to 1 pg/mL) were tested in these experiments. As expected, the cytotoxic activity of IFN-primed N K cells was higher than that of unprimed NK cells, and IL-2-primed N K cells exhibited the highest level of cell-mediated cytotoxicity against Eskol and K-562 cells (not shown).
2-CdA increases the sensitivity of HCL cells to NK-CMC.
The susceptibility ofEskol cells (Fig 3) and the other HCL cell lines (IRES-4, HS-1, and HS-2; not shown) to NK-CMC was increased significantly (P < .O 1 to P < .005), compared with untreated cultures, following preincubation of the tumor cells with 2-CdA (1 ng/mL to 1 pg/mL). The effect was found to be dose dependent (Fig 3) . The sensitivity of the HCL cells to either IFN-primed NK or IL-2-primed N K cell activities was also increased when the target cells were pretreated with 2-CdA (not shown). Only relatively high doses (100 ng/mL and 1 pg/mL) of 2-CdA increased the sensitivity of FS-4 cells to NK-CMC (not shown). (Fig 4A, B, C) . Combined treatment of target cells with IFN-Con 1 and 2-CdA can abol- Effector : target ratio ish this protective effect. A dose-dependent relationship in 2-CdA action was found: low doses of 2-CdA (1 and 10 ng/ mL) only increased (significance P < .OS) the sensitivity of Eskol, HS-I, and HS-2 cells to NK activity, whereas high doses (100 ng/mL and 1 pg/mL) of 2-CdA resulted in (significance P < .O 1 and P < .005) abolishment ofthe protective effect against NK-CMC induced by IFN (Fig 4A, B, C (Table I) . Thus, it seems that 2-CdA affects Eskol cells in postbinding phase of the killing process. IFN reduces the ability of tumor cells to induce activation of effector cells and NKCF release following effector celltarget cell conjugate formation. 2-CdA did not show a significant effect in this step of the killing process (not shown). Eskol cell-effector cell supernatants containing NKCF were assayed for their cytotoxic activity on either K-562 or Eskol target cells. Treatment of Eskol cells with IFN-Con 1 (300 U/ mL) significantly (P < .05) reduced the NKCF production by effector cells. 2-CdA (1 pglmL) did not change significantly the level of NKCF release, whereas combination treatment of IFN and 2-CdA resulted in similar NKCF production as seen in IFN treatment alone (not shown). However, 2-CdA treatment did have an effect on the susceptibility of target cells to cytotoxic activity of crude preparations of NKCF. It was found that 2-CdA increased significantly (P < .01 to P < .001) and in a dose-dependent manner the sensitivity of Eskol cells to NKCF activity (Fig 6) . In this stage of killing, IFN is not involved. Combination treatment of 2-CdA with IFN had the same effect as 2-CdA treatment alone; ie, enhancement of the susceptibility of the tumor cells to crude preparations of NKCF (Fig 6) . 2-CdA is a congener of deoxyadenosine that is resistant to adenosine deaminase activity. 2-CdA was found to be very effective drug against HCL.6-8 We have found that both Eskol and IRES-4 cells exhibit a similar level of sensitivity to the cytotoxic effect of 2-CdA. IFN-a appears to be capable of inducing a clinical response in about 80% of patients with HCL, but the rate of complete remission is low (10% to 1 5%).30-32 Piro et a16 have reported that 2-CdA administered as a single 7-day infusion produced complete remissions in 1 I of 12 patients with HCL, that the twelfth patient obtained a partial remission, that there had been no recurrence of disease in any patient at a median follow-up of over a year, and that, aside from fever without apparent infection, the treatment was without toxicity. Recently, other clinical trials confirmed these findings.',' It seems that our HCL IFN-sensitive and IFN-resistant cells may reflect (at least) two types of naturally occurring HCL cells. Both types of cells were found to be very sensitive to 2-CdA treatment. The relevance and the possible correlation of these results to the clinical response to IFN-a and IFN-Con1 and 2-CdA in patients with HCL should be studied.
In the last few years, clinical trials of combination of IFNa with chemotherapeutic drugs in cancer patients have been described. It was suggested that chemoimmunotherapy of tumors may involve first a reduction in the tumor load by chemotherapeutic agents. Surviving tumor cells may then be removed by immune defence cells, such as the NK cell population, the activity of which can be increased by immuno- agents such as the pyrimidine analogue 5-FU have been reClinical trials on patients with colon carcinoma, renal cell carcinoma, and other diseases revealed that such a combination is also clinically significant.'@-l3 We have investigated the role of this combination on the in vitro regulation of the natural killing arm of the immune system. 38 Because both IFN-a and the purine analogue 2-CdA are effective drugs against HCL, we investigated in the present study both the direct cell growth inhibitory effects and the effect on the regulation of the NK system following such as combination treatment. We have found that although 2-CdA suppression of NK activity (which was tested at doses corresponding to the therapeutic levels of the drug) suggests that the NK parameter of the immune system is functional in the presence of either 5-RI or 2-CdA, at least in the time measured. It is possible that the effect of the chemotherapeutic agents on the immune system is based on drug selectivity. In this respect, the large granular lymphocytes associated with NK activity may possess membrane characteristics that do not allow these agents to penetrate into the cytoplasm and Competitor cell : target cell ratio exert an immunosuppressive effect.39 It seems that at least two different intracellular mechanisms are involved in the effects induced by 2-CdA. Following a short time (8 h) of incubation, no cytotoxic effect of 2-CdA can be measured. However, using the same concentrations of 2-CdA, this time of incubation is sufficient to increase the sensitivity of the target cells to NK-CMC and to abolish the protective effect against NK-CMC induced by IFN.
Even though an exact mechanism of action of 2-CdA still remains obscure, it is evident that 2-CdA causes the prompt accumulation of DNA strand breaks in both normal lymphocytes and CLL cells.4o Increased poly (adenosine diphosphate [ADP]-ribose) synthesis is a well-established response to DNA-damaging chemicals; this response lowers cellular NAD pools!' NAD plays a pivotal role in cellular metabolism; lowering NAD concentrations inhibits glycolysis and adenosine triphosphate (ATP) generation, and reduces nicotinamide adenine dinucleotide phosphate (NADP) concentrations. Additional studies should be done in order to understand the molecular mechanisms involved in the additive/ synergistic cell growth inhibitory activities induced by com- We used in our experiments crude preparations of NKCF. Because both TNF and IFN-y are present in peripheral blood lymphocytes-target cell supernatants, one can argue that these cytokines may be responsible for cytotoxicity, alone or in combination. However, NKCF does differ from tumor necrosis factor (TNF) in number of important and its lytic activity cannot be substantially attributed to TNF.
IF"-./ presents in crude NKCF preparations4' may exhibit a role in NKCF cytotoxicity. However, we have shown that unlike IFN-a, exogenous IFN-y did not affect Eskol cell susceptibility to NK-CMC. Exogenous IFN-a induced protection against NK-CMC, but it did not affect the sensitivity of the hairy leukemic cells to NKCF. Thus, although crude preparations of NKCF may contain TNF and IFN-y, it seems that these cytokines do not play a central role in cell cytotoxicity induced by supernatants containing NKCF.
More studies are needed in order to examine the effect of 2-CdA treatment on the sensitivity of tumor cells to other immune cell-cytotoxic mechanisms, including the cytotoxic T lymphocytes (CTLs), TNF, antibody-dependent cell cytotoxicity (ADCC), and the complement system. In our studies, we have found that 2-CdA is more effective on HCL cells than on normal fibroblast cultures, although relatively high doses of 2-CdA had a direct cytotoxic effect on the fibroblasts and also increased the sensitivity of these cells to NK-CMC. Combination of IFN-Con1 and low doses of 2-CdA resulted in synergistic cell growth inhibitory effects on the HCL cells as well as increased their sensitivity to NK cytotoxicity. These low concentrations of 2-CdA had almost no effect on normal fibroblasts. Thus, it seems that the combination of 2-CdA and IF"-Con1 or IFN-a may be useful in clinical trials in patients with HCL. The relevant doses of 2-CdA and IFN that will affect the tumor cells but not the normal cells under in vivo conditions has to be determined.
Although the molecular mechanisms involved in the in- by 2-CdA.
